Author Angela De Palma, Ph.D. of GEN News recently highlighted the growing practice of using genetic engineering to improve pharmaceutical manufacturing productivity. Her article, in particular, focuses on the genetic engineering of Chinese Hamster Ovary (CHO) cells for the production of recombinant proteins.
Dr. Freeman (bioproduction manager at Horizion Discovery) believes that in the future, genome engineering of CHO cells will bring about substantial improvements in what cells are capable of, and not just facilitate selection of high producers. Genetic manipulations, for example, could reduce the bioreactor run time needed to generate the requisite amount of product.
Historically, cell-line performance has been enhanced through media, feed, and process optimization, primarily by fine-tuning these factors toward high growth and productivity. However, omics, CHO genome sequencing, and enhancements in genome editing have enabled scientists to take a more direct route in cell-line optimization through the modification of specific genes that directly affect cell culture performance or protein quality.
-Angela De Palma, PhD of GEN News. Read the full GEN News article here.
Genetic Engineering at Boston Mountain Biotech
While this article primarily focuses on improvements to CHO based on increased recombinant protein titer, stability, and proper folding, we at BMB believe that genetic modification to improve downstream purification are just as important. Our goal is to provide strategic CHO modifications that can be implemented to simplify protein chromatography that can be coupled with the modifications described in this article. This merger opens the potential to replace the typical Protein A initial capture step with a less expensive non-affinity resin.